open access

Vol 4, No 5 (2015)
Case reports
Published online: 2015-12-18
Get Citation

Novel therapeutic option in type 2 diabetes patients — practical experience with canagliflozin, SGLT2 inhibitor

Alicja Milczarczyk, Edward Franek, Edyta Cichocka, Janusz Gumprecht
DOI: 10.5603/DK.2015.0024
·
Diabetologia Kliniczna 2015;4(5):204-209.

open access

Vol 4, No 5 (2015)
Case reports
Published online: 2015-12-18

Abstract

Sodium glucose co-transporter 2 inhibitors (SGLT2i) were introduced into Polish Diabetes Association Clinical Guidelines in 2014 in combination with other antihyperglycemic agents. In our paper we describe clinical cases of using SGLT2 inhibitor — canagliflozin as an add-on therapy in two different combinations. The first case refers to the patient with inadequately controlled type 2 diabetes, associated with obesity, hypertension and dyslipidemia. Due to the profile of the patient it was decided to add canagliflozin to insulin therapy and metformin, which resulted in improvements in glycemic control, body weight reduction, as well as reduction in insulin dose. In the second patient treated with metformin in monotherapy, addition of canagliflozin was associated with improved glycemic control and reduced body weight, which positively affected patient’s motivation to continue treatment. Through the mechanism of targeting kidney instead of pancreas it is possible to combine this group of drugs with virtually all currently available antihyperglycemic treatments and in patients at various stages of type 2 diabetes.

Abstract

Sodium glucose co-transporter 2 inhibitors (SGLT2i) were introduced into Polish Diabetes Association Clinical Guidelines in 2014 in combination with other antihyperglycemic agents. In our paper we describe clinical cases of using SGLT2 inhibitor — canagliflozin as an add-on therapy in two different combinations. The first case refers to the patient with inadequately controlled type 2 diabetes, associated with obesity, hypertension and dyslipidemia. Due to the profile of the patient it was decided to add canagliflozin to insulin therapy and metformin, which resulted in improvements in glycemic control, body weight reduction, as well as reduction in insulin dose. In the second patient treated with metformin in monotherapy, addition of canagliflozin was associated with improved glycemic control and reduced body weight, which positively affected patient’s motivation to continue treatment. Through the mechanism of targeting kidney instead of pancreas it is possible to combine this group of drugs with virtually all currently available antihyperglycemic treatments and in patients at various stages of type 2 diabetes.

Get Citation

Keywords

sodium glucose co-transporter 2 inhibitor, canagliflozin, type 2 diabetes, glycemic control, body weight reduction

About this article
Title

Novel therapeutic option in type 2 diabetes patients — practical experience with canagliflozin, SGLT2 inhibitor

Journal

Clinical Diabetology

Issue

Vol 4, No 5 (2015)

Pages

204-209

Published online

2015-12-18

DOI

10.5603/DK.2015.0024

Bibliographic record

Diabetologia Kliniczna 2015;4(5):204-209.

Keywords

sodium glucose co-transporter 2 inhibitor
canagliflozin
type 2 diabetes
glycemic control
body weight reduction

Authors

Alicja Milczarczyk
Edward Franek
Edyta Cichocka
Janusz Gumprecht

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Diabetologia Kliniczna dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl